Takeda reports positive TAK-881 PID trial results

• Takeda Pharmaceutical (NYSE:TAK) announced detailed results from its Phase 2/3 IgGNITE clinical trial evaluating investigational TAK-881, a facilitated subcutaneous immunoglobulin 20% therapy for patients with primary immunodeficiency disease (PID).
• The study met its primary endpoint, demonstrating pharmacokinetic comparability between TAK-881 and HYQVIA, an established immunoglobulin therapy.
• TAK-881 reduced infusion volume by 50% and shortened infusion times while maintaining up to once-monthly dosing.

Takeda Pharmaceutical (NYSE:TAK) presented new data from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating TAK-881 Immune Globulin Subcutaneous (Human), 20% Solution combined with recombinant human hyaluronidase.

The data were presented at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID 2026).

Previously reported topline results showed that TAK-881 achieved its primary endpoint by demonstrating pharmacokinetic comparability with HYQVIA.

Secondary analyses showed infection outcomes, safety, and tolerability results consistent with established immunoglobulin replacement therapies in participants aged 16 years and older.

The newly presented results showed TAK-881 delivered the same immunoglobulin dose using 50% less volume compared with HYQVIA. Median infusion times were reduced by 56.2 minutes, or 42.6%, when administered through one infusion site.

Takeda said the results highlight the potential of TAK-881 to reduce treatment burden for patients with PID who require lifelong immunoglobulin replacement therapy.

The TAK-881-3001 study evaluated pharmacokinetics, efficacy, safety, tolerability, and immunogenicity in adults and children aged 2 years and older with PID who had previously received immunoglobulin therapy.

Participants aged 16 years and older entered a randomized crossover comparison of TAK-881 and HYQVIA, while participants younger than 16 years received TAK-881 in a separate single-arm cohort.

If approved, TAK-881 could become the first facilitated SCIG 20% therapy designed for administration every three to four weeks in patients with primary immunodeficiency disease.

Takeda develops medicines across areas including oncology, gastroenterology, rare diseases, plasma-derived therapies, and vaccines.